These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36731064)

  • 1. Reply to Kamp
    Hatabu H; Kaye KM; Christiani DC
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1108. PubMed ID: 36731064
    [No Abstract]   [Full Text] [Related]  

  • 2. α
    Kimura RH; Sharifi H; Shen B; Berry GJ; Guo HH
    Am J Respir Crit Care Med; 2023 Jun; 207(12):1633-1635. PubMed ID: 36693032
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel Insight into Pulmonary Fibrosis and Long COVID.
    Kamp JC; Werlein C; Plucinski EKJ; Neubert L; Welte T; Lee PD; Tafforeau P; Walsh C; Kuehnel MP; Schuppan D; Hoeper MM; Jonigk DD; Ackermann M
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1105-1107. PubMed ID: 36731065
    [No Abstract]   [Full Text] [Related]  

  • 4. Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series.
    Marwah V; Choudhary R; Malik V; Pemmaraju A; Peter D
    Adv Respir Med; 2021; 89(6):589-596. PubMed ID: 34966994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection.
    Earl N; Schoeneberg D; Davidson PD
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological findings based comparison of functional status in patients who have post-covid lung injury or idiopathic pulmonary fibrosis.
    Kızılırmak D; Sarı S; Can F; Havlucu Y
    BMC Pulm Med; 2023 Jun; 23(1):234. PubMed ID: 37391786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary fibrosis in a dog as a sequela of infection with Severe Acute Respiratory Syndrome Coronavirus 2? A case report.
    Colitti B; Manassero L; Colombino E; Ferraris EI; Caccamo R; Bertolotti L; Bortolami A; Bonfante F; Papa V; Cenacchi G; Calabrese F; Bozzetta E; Varello K; Capucchio MT; Rosati S
    BMC Vet Res; 2022 Mar; 18(1):111. PubMed ID: 35317791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis.
    Sgalla G; Magrì T; Lerede M; Comes A; Richeldi L
    Am J Respir Crit Care Med; 2022 Jul; 206(2):219-221. PubMed ID: 35412453
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.
    Vancheri C; Kreuter M; Richeldi L; Quaresma M; Stowasser S; Wuyts WA
    Am J Respir Crit Care Med; 2018 Oct; 198(8):1105-1106. PubMed ID: 30025211
    [No Abstract]   [Full Text] [Related]  

  • 10. Post covid 19 pulmonary fibrosis. Is it real threat?
    Rai DK; Sharma P; Kumar R
    Indian J Tuberc; 2021 Jul; 68(3):330-333. PubMed ID: 34099197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reply to Kobayashi
    Sui J; Kliment C
    Am J Respir Cell Mol Biol; 2024 Mar; 70(3):226-227. PubMed ID: 38128102
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Nett
    Culver DA; Kim H
    Am J Respir Crit Care Med; 2020 Feb; 201(4):496-497. PubMed ID: 31664851
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to D'Alessandro-Gabazza et al.: Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.
    Espindola MS; Habiel DM; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Oct; 198(7):971-973. PubMed ID: 29979883
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Puxeddu
    Byrne A
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1446-1447. PubMed ID: 31347919
    [No Abstract]   [Full Text] [Related]  

  • 15. New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis.
    Upadhya P; Chary R; Chawla G; Vadala R; Mohanty M
    Adv Respir Med; 2021; 89(1):84-85. PubMed ID: 33471349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Sun
    Sun YY; Wang L; Liu JM; Yuan P
    Am J Respir Crit Care Med; 2022 Jan; 205(2):254. PubMed ID: 34739352
    [No Abstract]   [Full Text] [Related]  

  • 17. A silent march-Post covid fibrosis in asymptomatics - A cause for concern?
    Antony T; Vishak Acharya K; Unnikrishnan B; Keerthi NS
    Indian J Tuberc; 2023 Apr; 70(2):249-252. PubMed ID: 37100584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Post-COVID-19 pulmonary sequla: longterm follow up and management].
    Türktaş H; Oğuzülgen İK
    Tuberk Toraks; 2020 Dec; 68(4):419-429. PubMed ID: 33448739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19.
    Omote N; Kanemitsu Y; Inoue T; Yonezawa T; Ichihashi T; Shindo Y; Sakamoto K; Ando A; Suzuki A; Niimi A; Ito S; Imaizumi K; Hashimoto N
    Intern Med; 2022 Jan; 61(2):233-236. PubMed ID: 34744107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Kobayashi
    Kondoh Y; Azuma A; Tagawa J; Yamamori N; Homma S
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1450-1451. PubMed ID: 32150449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.